56 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
in writing, any person of any Personal Data or security-related incident. Neither the Company nor any Subsidiary has received any written notice of any … , the Company hereby agrees to pay all costs and expenses incident to the performance of its obligations hereunder, including the following: (i) all expenses
8-K
EX-1.2
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
to be performed or satisfied hereunder at or prior to such Closing Date.
(d) All corporate proceedings and other legal matters incident
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
shall pay all fees and expenses incident to the performance of or compliance with ARTICLE 5 of this Agreement by the Company, including without … of the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.
Each selling
8-K
EX-1.1
zdjv3leyqhji
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
ld13ag9hzk2gk
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
5o9pws3etis3 cq
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
49vltur7
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
embdiiu0yk9wpply0na
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
a4b1 awxw2se
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
zry805ss624 oeb
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
ljmo0
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
iapwjfwv7 cjbdqzqv8z
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm